Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03972462 · ClinicalTrials.gov registry record · Phase 1
NPC-12G Gel 0.2% Sirolimus PK Bridging Study
A Phase 1 study, sponsored by Nobelpharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03972462 is a Phase 1 study that has completed, run by Nobelpharma. The registered enrollment target is 12 participants.
The verdict
NCT03972462, a Phase 1 study, has completed, sponsored by Nobelpharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study is designed to describe the relative systemic bioavailability of topical and oral sirolimus formulations.
Interventions
- DRUG NPC-12G Gel 0.2%
- DRUG Rapamune® 2 mg tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-05-31 |
| Est. Completion | 2019-06-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03972462
The ClinicalTrials.gov registry entry for NCT03972462 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nobelpharma, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NPC-12G Gel 0.2% is the first listed.
NCT03972462 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03972462 about?
NCT03972462 is a clinical study titled "NPC-12G Gel 0.2% Sirolimus PK Bridging Study". This study is designed to describe the relative systemic bioavailability of topical and oral sirolimus formulations.
What is the current status of trial NCT03972462?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2019-05-31. Estimated completion is 2019-06-17.
What interventions are being tested in trial NCT03972462?
The interventions under investigation include: NPC-12G Gel 0.2% (DRUG), Rapamune® 2 mg tablet (DRUG).
Who is sponsoring clinical trial NCT03972462?
This trial is sponsored by Nobelpharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.